Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: A case report and immunological analysis

British Journal of Dermatology

Volumn 168, Issue 4, 2013, Pages 733-738

  Teulings, H E ^a,b   Tjin, E P M ^a   Willemsen, K J ^a   Krebbers, G ^a   Van Noesel, C J ^a   Kemp, E H ^c   Nieuweboer Krobotova, L ^a,b   Van Der Veen, J P W ^a,b   Luiten, R M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD68 ANTIGEN; DACARBAZINE; GRANZYME B;

AGED; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; CASE REPORT; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CHEMORADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DERMIS; DIAPEDESIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNITY; IMMUNOHISTOCHEMISTRY; LEUKODERMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MACROPHAGE; MALE; MELANOCYTE; MELANOMA; MELANOMA ASSOCIATED LEUCODERMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; SKIN BIOPSY; SKIN EXAMINATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AGED; B-LYMPHOCYTES; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE-FREE SURVIVAL; HUMANS; IMMUNITY, CELLULAR; MALE; MELANOMA; NEOPLASMS, RADIATION-INDUCED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VITILIGO;

EID: 84875442863     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12136     Document Type: Article

References (25)

1. Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658-63.
2. Bystryn JC, Rigel D, Friedman RJ, et al. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123: 1053-5.
3. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-8.
4. Duhra P, Ilchyshyn A,. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991; 16: 303-5.
5. Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21: 409-14.
6. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-18.
7. Agrawal S, Kane JM III, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115: 5836-44.
8. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13: 589-97.
9. Foote M, Burmeister B, Dwyer P, et al. An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection. Melanoma Res 2012; 22: 257-62.
10. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-32.
11. Waterman EA, Kemp EH, Gawkrodger DJ, et al. Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. Clin Exp Immunol 2002; 129: 527-32.
12. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008; 5: 557-61.
13. Abood A, Saleh DB, Watt DA,. Malignant melanoma and vitiligo: can radiotherapy shed light on the subject? J Plast Reconstr Aesthet Surg 2009; 62: e119-20.
14. Levine EL, Ribeiro GG,. Vitiligo and radiotherapy: the Koebner phenomenon demonstrated in patients with vitiligo undergoing radiotherapy for carcinoma of the breast. Clin Oncol (R Coll Radiol) 1994; 6: 133-4.
15. Pajonk F, Weissenberger C, Witucki G, et al. Vitiligo at the sites of irradiation in a patient with Hodgkin's disease. Strahlenther Onkol 2002; 178: 159-62.
16. Polat M, Yalcin B, Alli N,. Vitiligo at the site of radiotherapy for nasopharyngeal carcinoma. Am J Clin Dermatol 2007; 8: 247-9.
17. Weitzen R, Pfeffer R, Mandel M,. Benign lesions in cancer patients: case 3. Vitiligo after radiotherapy for breast cancer in a woman with depigmentation disorder. J Clin Oncol 2005; 23: 644.
18. Kim DH, Kim CW, Kim TY,. Vitiligo at the site of radiotherapy for malignant thymoma. Acta Derm Venereol 1999; 79: 497.
19. Koh HK, Sober AJ, Nakagawa H, et al. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983; 9: 696-708.
20. Hartmann A, Bedenk C, Keikavoussi P, et al. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges 2008; 6: 1053-9.
21. Demaria S, Bhardwaj N, McBride WH, et al. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63: 655-66.
22. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-70.
23. Safwat A, Schmidt H, Bastholt L, et al. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Radiother Oncol 2005; 77: 143-7.
24. Overgaard J, Gonzalez GD, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995; 345: 540-3.
25. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-31.